Renal progenitor cell therapy

Class

Autologous SOX9+CD73+ renal progenitor cell therapy (regenerative)

Renal progenitor cell therapy refers to the use of a specific subpopulation of kidney-derived progenitor cells, identified by the markers SOX9 and CD73, to promote repair of damaged kidney tissue. SOX9 is a transcription factor associated with cells that retain some regenerative capacity, similar to progenitor cells found in other organs that can proliferate and redifferentiate after injury. CD73 is a cell-surface enzyme often found on mesenchymal-like cells with anti-inflammatory properties. Selecting cells that express both markers is intended to isolate a population that combines tissue-forming potential with favorable signaling behavior, rather than using an unselected mixture of kidney cells, which would likely be less consistent in quality and effect. The kidney has limited intrinsic regenerative ability once nephrons—the functional filtering units—are lost or scarred, a process central to acute kidney injury and to the progression of chronic kidney disease toward fibrosis and functional decline. Using a patient's own (autologous) progenitor cells avoids the immune rejection risk associated with donor-derived cell therapies. The general rationale for this approach is to reintroduce or expand cells capable of engrafting into injured tubular structures, or of secreting factors that reduce inflammation and scarring, thereby slowing or partially reversing the loss of kidney function seen across various kidney diseases.